Wikisage, the free encyclopedia of the second generation, is digital heritage

Eslicarbazepine: Difference between revisions

From Wikisage
Jump to navigation Jump to search
(wlink todo)
Line 36: Line 36:
|}
|}


[[File:Wikidata-logo-en.svg.png|32px]]
{{Wikidata|Q410273}}
[https://www.wikidata.org/wiki/Q410273 Q410273]


==Bioequivalence==
==Bioequivalence==

Revision as of 19:35, 28 November 2016

S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]

Pharmacy and chemistry

Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]

Pharmacology

Mild inducers

After de Leon the following AED groups as mild inducers:

[5]

Cutaneous adverse effects

Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine

ATC code N03

eslicarbazepine
[6]

Q410273 at Wikidata  Interwiki via Wikidata


Bioequivalence

Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects

References